The Alzheimer’s Association International Conference (AAIC) is the largest and most influential international meeting dedicated to advancing dementia science. Each year, AAIC convenes the world’s leading basic science and clinical researchers, next generation investigators, clinicians, and the care research community to share research discoveries that will lead to better treatment and diagnosis of Alzheimer’s disease. Over 5000 thousand attendees from 68 countries gathered this year at the AAIC in Chicago during the 14th – 18th of July, to share their knowledge in the field of dementia research.
For the first time EPAD study was exhibited. The EPAD booth was a great meeting area for catching up with the many current and future EPAD collaborators. Nearly 400 people stopped by at the EPAD booth to hear about the study and exchange ideas. The aim of the booth was to introduce the EPAD study and to showcase the EPAD PoC trial platform. At the satellite symposium dedicated to the EPAD PoC trial the EPAD leadership presented the platform and addressed a great set of questions from the audience. EPAD was also mentioned at numerous talks during the AAIC. Miia Kivipelto (Professor at the Karolinska Institute) in her plenary session highlighted the EPAD study as one of the world leading initiatives. AMYPAD, EPAD sister project, was presented with two posters and a great oral presentation “Amyloid Staging Models: Generalizability and Validation”, given by Lyduine Collij, VUmc. AMYPAD was as well mentioned in several other presentations, such as Gil Rabinovici`s plenary talk “Pathogenesis of Alzheimer’s Disease: What Have We Learned From Neuroimaging?”.
Next year AAIC will bring together world leaders in dementia research in Los Angeles.
More about EPAD at http://ep-ad.org/.
More about AMYPAD at https://amypad.eu/.